|Articles|May 25, 2022

The benefits of end-to-end formulation and fill-finish of biologics

Author(s)Curia

The clinical value of biologics for the treatment of many disease indications has been accompanied by phenomenal sales. By 2026, the global market for biologics is projected to increase to $537 billion. However, getting a promising drug candidate from formulation development to clinical phase production and commercial manufacturing can be daunting. Proper formulation development has a huge impact on whether a technology transfer to clinical phase fill-finish is successful. Learn more!

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.